Moderna (MRNA) PT Raised to $125 at Jefferies ahead of RSV launch and CMV data

Jefferies analyst Michael Yee raised the price target on Moderna (NASDAQ: MRNA) to $125.00 (from $115.00) while maintaining a Buy rating.

The analyst commented: 'Near term focus is around (1) RSV launch (PDUFA 5/12) where co feels confident on solid positioning with PFS + pot'l contracting with pharmacies post-approval; (2) Phase III CMV data coming by YE/24 and co feels confident they could hit on the interim; (3) Enrollment in Phase III confirmatory cancer vaccine study in adjuvant melanoma is picking up + this is a good update for the FDA and could drive a pot'l early filing for accelerated approval later this year. Our price target of $125 is based on an NPV of the discounted probability-based sum of the parts, including its vast pipeline."

You May Also Be Interested In

• York Space Systems (YSS) PT Lowered to $15 at Jefferies
• JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation